Evidence map›Paper›PMID 36388185›Full record

ArticleFrontiers in neurology2022

Biomarker of early neurological deterioration in minor stroke and proximal large vessel occlusion: A pilot study.

Zhiqiang Wang, Shuai Wang, Yuxia Li, Rongyu Wang, Lianyan Jiang, Bo Zheng, Yaodan Zhang, Qingsong Wang, Jian Wang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhiqiang WangDepartment of Neurology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Shuai WangDepartment of Outpatient, The General Hospital of Western Theater Command, Chengdu, China.
Yuxia LiDepartment of Neurology, Chengdu BOE Hospital, Chengdu, China.
Rongyu WangDepartment of Neurology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Lianyan JiangDepartment of Neurology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Bo ZhengDepartment of Neurology, Ya'an People's Hospital, Ya'an, China.
Yaodan ZhangDepartment of Neurology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Qingsong WangDepartment of Neurology, The General Hospital of Western Theater Command, Chengdu, China.
Jian WangDepartment of Neurology, Ya'an People's Hospital, Ya'an, China.
Chengdu University of Traditional Chinese Medicine · CNChengdu Military General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Plasma neurofilament light chain (pNFL) represents one of the scaffolding proteins of central nervous system axonal injury. The aim of this study was to evaluate pNFL as a predictive biomarker for early neurological deterioration (END) in medically managed patients with large vessel occlusion (LVO) and mild presentation (NIHSS < 6). Methods: This retrospective study was developed from a prospectively collected stroke database, which was conducted at a large academic comprehensive stroke center in western China. Patients who first presented with acute ischemic stroke (AIS) within 24 h of symptom onset were continuously included. Stroke severity was analyzed at admission using the NIHSS score. The pNFL drawn on admission was analyzed with a novel ultrasensitive single-molecule array. Results: Thirty-nine consecutive patients were included in the analysis, and 19 (48.72%) patients experienced END. Patients who experienced END had significantly higher pNFL levels (mean, 65.20 vs. 48.28 pg/mL; Conclusion: END in minor stroke with LVO was distinguishable from those without END following the determination of pNFL in the blood samples within 24 h of onset. The pNFL is a promising biomarker of END in minor stroke with LVO. Clinical trial registration: ChiCTR1800020330.

Indexed as

biomarkersearly neurological deteriorationlarge vessel occlusionminor strokeneurofilament light

Identifiers

PMID36388185
PMCPMC9642090
OpenAlexW4309413003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.